ESPR Esperion Therapeutics Inc.

Esperion to Participate in Upcoming 2024 Cantor Global Healthcare Conference

Esperion to Participate in Upcoming 2024 Cantor Global Healthcare Conference

ANN ARBOR, Mich., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that the company will be participating in the webcasted 2024 Cantor Global Healthcare Conference on Thursday, September 19, 2024, at 10:55 a.m. ET.

The live webcast can be accessed on the investor and media section of the Esperion . Access to the webcast replay will be available approximately two hours after the completion of the call and will be archived on the Company’s website for approximately 90 days.

Esperion Therapeutics

At Esperion, we discover, develop, and commercialize innovative medicines to help improve outcomes for patients with or at risk for cardiovascular and cardiometabolic diseases. The status quo is not meeting the health needs of millions of people with high cholesterol – that is why our team of passionate industry leaders is breaking through the barriers that prevent patients from reaching their goals. Providers are moving toward reducing LDL-cholesterol levels as low as possible, as soon as possible; we provide the next steps to help get patients there. Because when it comes to high cholesterol, getting to goal is not optional. It is our life’s work. For more information, visit and and follow us on X at

Esperion Contact Information:

Investors:

Alina Venezia



(734) 887-3903

Media:

Tiffany Aldrich



(616) 443-8438



EN
05/09/2024

Underlying

ESPREsperion Therapeutics Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Esperion Therapeutics Inc.

 PRESS RELEASE
Free
ESPR Esperion Therap...

Esperion EU Partner Reports Final Real-World Results from MILOS German...

Esperion EU Partner Reports Final Real-World Results from MILOS German Cohort Demonstrating Strong Increase in LDL-C Goal Achievement With Addition of Bempedoic Acid – Patients Prescribed Bempedoic Acid, As Well As Bempedoic Acid and Ezetimibe, With or Without Other Lipid Lowering Therapies, Showed A One-Third Relative Reduction in Low-Density LDL-C From Pre-Treatment To 2-Years in the MILOS Study – – Real-World Results Demonstrated ~7-Fold Increase in Proportion of Patients Achieving LDL-C Goals When Treated With Bempedoic Acid or Bempedoic Acid and Ezetimibe – – Data From the MILOS Germ...

8h / 30m 1 EN
 PRESS RELEASE
Free
ESPR Esperion Therap...

Esperion Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(...

Esperion Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) ANN ARBOR, Mich., Sept. 25, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that on September 23, 2024, the Company granted one new employee 3,500 restricted stock units (RSUs) under Esperion’s 2017 Inducement Equity Incentive Plan. The 2017 Inducement Equity Incentive Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee or non-employee director of Esperion (or following a bona fide period of non-employment), as an inducement material to such ind...

September 25, 2024 1 EN
 PRESS RELEASE
Free
ESPR Esperion Therap...

Esperion to Participate in Upcoming 2024 Cantor Global Healthcare Conf...

Esperion to Participate in Upcoming 2024 Cantor Global Healthcare Conference ANN ARBOR, Mich., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that the company will be participating in the webcasted 2024 Cantor Global Healthcare Conference on Thursday, September 19, 2024, at 10:55 a.m. ET. The live webcast can be accessed on the investor and media section of the Esperion . Access to the webcast replay will be available approximately two hours after the completion of the call and will be archived on the Company’s website for approximately 90 days. Esperion Ther...

September 5, 2024 1 EN
 PRESS RELEASE
Free
ESPR Esperion Therap...

Esperion Secures Additional Commercial and Medicare Formulary Coverage...

Esperion Secures Additional Commercial and Medicare Formulary Coverage for NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) – New Additions to Medicare Formularies at Optum/United AARP and CVS/SilverScript Coupled with Humana Provides Access to More Than 65% of Medicare Insured Lives and More Than 92% of Commercially Insured Lives – – Increased Coverage and Improved Prior Authorization Processes Make Prescribing NEXLETOL and NEXLIZET Easier for Healthcare Providers – – NEXLETOL and NEXLIZET are the Only Non-Statins FDA Approved to Lower LDL Cholesterol and Reduce Ri...

September 3, 2024 1 EN
 PRESS RELEASE
Free
ESPR Esperion Therap...

Esperion to Participate in Upcoming H.C. Wainwright 26th Annual Global...

Esperion to Participate in Upcoming H.C. Wainwright 26th Annual Global Investment Conference ANN ARBOR, Mich., Aug. 26, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that the company will be participating in the webcasted H.C. Wainwright 26th Annual Global Investment Conference on Monday, September 9, 2024, at 8:30 a.m. ET. The live webcast can be accessed on the investor and media section of the Esperion . Access to the webcast replay will be available approximately two hours after the completion of the call and will be archived on the Company’s website for approximat...

August 26, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch